Actavis Counting On Strong Product Line Depth For Avycaz Launch
The specialty pharma will take advantage of its presence in antibiotics to launch its third FDA-approved antibiotic for hard-to-treat infections before the end of the second quarter.
You may also be interested in...
Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.
Achaogen has designed a registration program with a single Phase III study for its next-generation aminoglycoside, plazomicin, to treat serious infections due to carbapenem-resistant Enterobacteriaceae, in what could be an interesting test for potential modifications to the standard approval pathway.
The acquisition of the late-stage injectable antibiotic could launch ahead of Orapem.